When a DNA repair gene turns rogue: EXO1 as a new cancer target
Penn State researchers found that the EXO1 protein, which normally protects DNA, begins to damage it when overproduced, creating a BRCA-like vulnerability in tumor cells.
- The EXO1 gene, which normally repairs DNA, starts to damage it in tumor cells when overproduced.
- EXO1 is overexpressed in 20 to 30 percent of breast and ovarian tumors, as well as melanoma and others.
- Tumors with high EXO1 behave like cells carrying a BRCA mutation even when no such mutation is present.
- The study was published by Penn State researchers in the journal Nature Communications.
Researchers at Penn State College of Medicine have shown that the EXO1 gene, whose usual job is to protect and repair DNA, can switch sides inside tumor cells. When cancer cells produce too much of the protein, it begins to damage genetic material instead of preserving it. The research was published in the journal Nature Communications and is authored by Aleksandra Nusavardhana, Claudia Nicolae and George-Lucian Moldovan.
The heart of the finding is that this instability behaves, in the lab, much like the well-known BRCA mutations. Tumors with high EXO1 levels show the same patterns, including response to chemotherapy, even when no classic BRCA mutation is present. That matters because targeted therapies already exist for BRCA tumors, which raises the question of whether they could be extended to patients without that mutation.
The numbers give context for why this could be relevant to a large number of people. According to the study, EXO1 is overexpressed in 20 to 30 percent of breast and ovarian tumors, but it also appears in melanoma and in testicular, cervical and hepatobiliary cancers. This is, in other words, a mechanism not tied to a single type of cancer.
How does a DNA guardian become a threat?
DNA is constantly damaged and repaired in every cell, and EXO1 is part of that maintenance machinery. The problem lies in dosage. As long as it is present in normal amounts, the protein does useful work. When there is too much of it, the balance breaks down and the repair tool itself starts introducing errors. In cancer cells, which are already prone to genetic instability, that excess becomes an added weakness.
That weakness is exactly what interests researchers. Oncology has spent years searching for so-called tumor vulnerabilities, points where a cancer cell can be targeted more precisely than a healthy one. If high EXO1 creates a state resembling a BRCA defect, then drugs that exploit that defect might also work on tumors that did not previously belong to that group.
What does this not prove yet?
It is worth being precise about the limits. This is a mechanism described under laboratory conditions and through analysis of tumor samples, not a finished therapy. The study shows an association between high EXO1 and BRCA-like behavior, but it does not claim that treatment is proven in patients. The authors themselves say they plan further research aimed at clinical trials in people whose tumors overproduce this protein.
That means any eventual use in the clinic could be a long way off, with the usual steps of safety and efficacy checks. Still, the direction is intriguing because it tries to point existing, already approved approaches at a wider group of patients. If EXO1 is confirmed as a reliable marker, what would a test look like that tells doctors, before treatment, whether a tumor falls into that sensitive group?
